Discovery of naturally processed and HLA-presented class I peptides from vaccinia virus infection using mass spectrometry for vaccine development.

An important approach for developing a safer smallpox vaccine is to identify naturally processed immunogenic vaccinia-derived peptides rather than live whole vaccinia virus. We used two-dimensional liquid chromatography coupled to mass spectrometry to identify 116 vaccinia peptides, encoded by 61 open reading frames, from a B-cell line (homozygous for HLA class I A*0201, B*1501, and C*03) after infection with vaccinia virus (Dryvax). Importantly, 68 of these peptides are conserved in variola, providing insight into the peptides that induce protection against smallpox. Twenty-one of these 68 conserved peptides were 11 amino acids long or longer, outside of the range of most predictive algorithms. Thus, direct identification of naturally processed and presented HLA peptides gives important information not provided by current computational methods for identifying potential vaccinia epitopes.

[1]  Jennifer N. Sutton,et al.  Use of selected reaction monitoring mass spectrometry for the detection of specific MHC class I peptide antigens on A3 supertype family members , 2005, Cancer Immunology, Immunotherapy.

[2]  Nina Hillen,et al.  Contribution of mass spectrometry-based proteomics to immunology , 2006, Expert review of proteomics.

[3]  R. Kennedy,et al.  T‐Cell epitope discovery for variola and vaccinia viruses , 2007, Reviews in medical virology.

[4]  Alexey I Nesvizhskii,et al.  Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. , 2002, Analytical chemistry.

[5]  K. Parker,et al.  Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. , 1994, Journal of immunology.

[6]  D. Koboldt,et al.  The immunogenetics of smallpox vaccination. , 2007, The Journal of infectious diseases.

[7]  R. Vierkant,et al.  Identification and Characterization of Novel, Naturally Processed Measles Virus Class II HLA-DRB1 Peptides , 2004, Journal of Virology.

[8]  R. Jacobson,et al.  Heterogeneity in Vaccine Immune Response: The Role of Immunogenetics and the Emerging Field of Vaccinomics , 2007, Clinical pharmacology and therapeutics.

[9]  Cécile Gouttefangeas,et al.  Identification of tumor‐associated MHC class I ligands by a novel T cell‐independent approach , 2000, European journal of immunology.

[10]  Steven P Gygi,et al.  Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry , 2007, Nature Methods.

[11]  R. Henderson,et al.  Recognition of human melanoma cells by HLA-A2.1-restricted cytotoxic T lymphocytes is mediated by at least six shared peptide epitopes. , 1993, Journal of immunology.

[12]  Magdalini Moutaftsi,et al.  A consensus epitope prediction approach identifies the breadth of murine TCD8+-cell responses to vaccinia virus , 2006, Nature Biotechnology.

[13]  C. Chu,et al.  Purification and characterization of a naturally processed hepatitis B virus peptide recognized by CD8+ cytotoxic T lymphocytes. , 1996, The Journal of clinical investigation.

[14]  C. Herberts,et al.  A microcapillary column switching HPLC-electrospray ionization MS system for the direct identification of peptides presented by major histocompatibility complex class I molecules. , 1998, Analytical chemistry.

[15]  H. Rammensee,et al.  SYFPEITHI: database for MHC ligands and peptide motifs , 1999, Immunogenetics.

[16]  C. Boog,et al.  Mass Tag-Assisted Identification of Naturally Processed HLA Class II-Presented Meningococcal Peptides Recognized by CD4+ T Lymphocytes , 2005, The Journal of Immunology.

[17]  F. Ennis,et al.  Human Cytotoxic CD4+ T Cells Recognize HLA-DR1-Restricted Epitopes on Vaccinia Virus Proteins A24R and D1R Conserved among Poxviruses1 , 2007, The Journal of Immunology.

[18]  Koplan Jp,et al.  Smallpox vaccination reactions, prophylaxis, and therapy of complications. , 1975 .

[19]  A. Harris,et al.  Immunodominance of Poxviral-Specific CTL in a Human Trial of Recombinant-Modified Vaccinia Ankara1 , 2005, The Journal of Immunology.

[20]  F. Ennis,et al.  Immunologic responses to vaccinia vaccines administered by different parenteral routes. , 1997, The Journal of infectious diseases.

[21]  F. Falkner,et al.  The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. , 1998, Virology.

[22]  M. Mann,et al.  Parts per Million Mass Accuracy on an Orbitrap Mass Spectrometer via Lock Mass Injection into a C-trap*S , 2005, Molecular & Cellular Proteomics.

[23]  C. Walker,et al.  Class I major histocompatibility complex-restricted cytotoxic T cell responses to vaccinia virus in humans. , 1993, The Journal of general virology.

[24]  J. Berzofsky,et al.  Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[25]  M. A. Saper,et al.  Structure of the human class I histocompatibility antigen, HLA-A2 , 1987, Nature.

[26]  Bjoern Peters,et al.  HLA class I-restricted responses to vaccinia recognize a broad array of proteins mainly involved in virulence and viral gene regulation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[27]  Bjoern Peters,et al.  HLA-A*0201, HLA-A*1101, and HLA-B*0702 Transgenic Mice Recognize Numerous Poxvirus Determinants from a Wide Variety of Viral Gene Products1 , 2005, The Journal of Immunology.

[28]  R. Aebersold,et al.  A statistical model for identifying proteins by tandem mass spectrometry. , 2003, Analytical chemistry.

[29]  S. Stevanović,et al.  Mass spectrometric identification of an HLA-A*0201 epitope from Plasmodium falciparum MSP-1. , 2008, International immunology.

[30]  C. Barnstable,et al.  Use of a monoclonal antibody (W6/32) in structural studies of HLA-A,B,C, antigens. , 1979, Journal of immunology.

[31]  H R Bergen,et al.  Mass Spectrometry and Peptide‐based Vaccine Development , 2007, Clinical pharmacology and therapeutics.

[32]  M F del Guercio,et al.  Specificity and degeneracy in peptide binding to HLA-B7-like class I molecules. , 1996, Journal of immunology.

[33]  D. Fremont,et al.  Structural Definition of the H-2Kd Peptide-binding Motif* , 2006, Journal of Biological Chemistry.

[34]  Albert J R Heck,et al.  Stable Isotope Tagging of Epitopes , 2006, Molecular & Cellular Proteomics.

[35]  B. Gückel,et al.  A MAGE-A1 HLA-A A*0201 epitope identified by mass spectrometry. , 2001, Cancer research.

[36]  O. Lund,et al.  novel sequence representations Reliable prediction of T-cell epitopes using neural networks with , 2003 .

[37]  Hans-Georg Rammensee,et al.  Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T cells and comparative analysis of smallpox vaccines , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[38]  V. Engelhard The contributions of mass spectrometry to understanding of immune recognition by T lymphocytes. , 2007, International journal of mass spectrometry.

[39]  V. Brusic,et al.  Long‐term T cell memory to human leucocyte antigen‐A2 supertype epitopes in humans vaccinated against smallpox , 2007, Clinical and experimental immunology.

[40]  F. Ennis,et al.  Human cytotoxic T-cell memory: long-lived responses to vaccinia virus , 1996, Journal of virology.

[41]  S. Ostroff,et al.  Myopericarditis following smallpox vaccination among vaccinia-naive US military personnel. , 2003, JAMA.

[42]  C. Upton,et al.  Genomic differences of Vaccinia virus clones from Dryvax smallpox vaccine: the Dryvax-like ACAM2000 and the mouse neurovirulent Clone-3. , 2007, Vaccine.

[43]  Stephen Naylor,et al.  The role of mass spectrometry in vaccine development. , 2001, Vaccine.

[44]  S Brunak,et al.  Sensitive quantitative predictions of peptide-MHC binding by a 'Query by Committee' artificial neural network approach. , 2003, Tissue antigens.

[45]  G. Poland,et al.  Identification of class II HLA-DRB1*03-bound measles virus peptides by 2D-liquid chromatography tandem mass spectrometry. , 2005, Journal of proteome research.

[46]  Bjoern Peters,et al.  Integrating epitope data into the emerging web of biomedical knowledge resources , 2007, Nature Reviews Immunology.

[47]  Bjoern Peters,et al.  A Quantitative Analysis of the Variables Affecting the Repertoire of T Cell Specificities Recognized after Vaccinia Virus Infection1 , 2007, The Journal of Immunology.

[48]  R. Henderson,et al.  Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. , 1992, Science.

[49]  Hans-Georg Rammensee,et al.  MHC ligands and peptide motifs: first listing , 2004, Immunogenetics.

[50]  H. Rammensee,et al.  Towards patient‐specific tumor antigen selection for vaccination , 2002, Immunological reviews.

[51]  C. Barnstable,et al.  Molecular structure of human histocompatibility antigens: the HLA‐C series , 1977, European journal of immunology.

[52]  G. Poland,et al.  Accurate mass precursor ion data and tandem mass spectrometry identify a class I human leukocyte antigen A*0201-presented peptide originating from vaccinia virus , 2005, Journal of the American Society for Mass Spectrometry.

[53]  C. Melief,et al.  Reduced cell surface expression of HLA-C molecules correlates with restricted peptide binding and stable TAP interaction. , 1998, Journal of immunology.

[54]  A Sette,et al.  Majority of peptides binding HLA-A*0201 with high affinity crossreact with other A2-supertype molecules. , 2001, Human immunology.

[55]  C. Melief,et al.  Identification of T-cell epitopes for cancer immunotherapy , 2007, Leukemia.

[56]  J. Sidney,et al.  Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism , 1999, Immunogenetics.

[57]  Lihan K. Yan,et al.  Dose-dependent neutralizing-antibody responses to vaccinia. , 2004, The Journal of infectious diseases.